Curosurf 80 mg/mL

Curosurf 80 mg/mL is a suspension containing poractant alfa, used for respiratory support in premature infants. This medication is administered via endotracheal route and is manufactured by Chiesi USA, Inc.

Curosurf 80 mg/mL is primarily used to treat respiratory distress syndrome (RDS) in premature infants. This condition often occurs due to a lack of surfactant in the lungs, which is crucial for proper lung function. The medication helps to improve breathing and reduce the need for mechanical ventilation. What is Curosurf used for? It is specifically designed to provide respiratory support in neonatal intensive care units.

Common effects of Curosurf 80 mg/mL may include improved lung function and reduced respiratory distress in premature infants. Some infants may experience temporary side effects such as changes in oxygen levels or mild respiratory symptoms. These effects are generally monitored closely by healthcare professionals.

Curosurf 80 mg/mL should be handled with care and administered by trained healthcare professionals. It is important to follow proper storage and handling guidelines to maintain the integrity of the medication. Always consult a healthcare provider for specific precautions and contraindications.

Curosurf 80 mg/mL may interact with other medications or treatments. It is important to inform healthcare providers about all current medications and treatments before administration. Specific interactions should be discussed with a healthcare professional to ensure safe and effective use.